Market capitalization | CHF763.12m |
Enterprise Value | CHF637.37m |
P/E (TTM) P/E ratio | 6.02 |
EV/FCF (TTM) EV/FCF | 4.27 |
EV/Sales (TTM) EV/Sales | 2.51 |
P/S ratio (TTM) P/S ratio | 3.00 |
P/B ratio (TTM) P/B ratio | 1.63 |
Dividend yield | 4.08% |
Last dividend (FY25) | CHF1.95 |
As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.
2 Analysts have issued a COSMO Pharmaceuticals forecast:
2 Analysts have issued a COSMO Pharmaceuticals forecast:
Dec '24 |
+/-
%
|
||
Revenue | 254 254 |
182%
182%
|
|
Gross Profit | 211 211 |
307%
307%
|
|
EBITDA | 150 150 |
711%
711%
|
EBIT (Operating Income) EBIT | 139 139 |
2,861%
2,861%
|
Net Profit | 127 127 |
2,816%
2,816%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Head office | Netherlands |
CEO | Giovanni Napoli |
Employees | 321 |
Founded | 2016 |
Website | www.cosmopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.